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Cefepime is a potentially useful antibiotic for treatment of infections with Enterobacter cloacae. However, in
our institution the MIC90 for E. cloacae bloodstream isolates is 16 g/ml. PCR amplification of bla genes
revealed that one-third (15/45) of E. cloacae bloodstream isolates produced SHV-type extended-spectrum
beta-lactamases (ESBLs) in addition to hyperproduction of AmpC-type beta-lactamases. The majority (11/15)
of ESBL producers also produced the TEM-1 beta-lactamase. The SHV types included SHV-2, -5, -7, -12, -14,
and -30. All but two of the ESBL-producing E. cloacae isolates, but none of the non-ESBL-producing strains,
had MICs of cefepime of >2 g/ml. The MIC90 for cefepime for ESBL-producing strains was 64 g/ml, while
for non-ESBL producers it was 0.5 g/ml. Using current Clinical and Laboratory Standards Institute break-
points for cefepime, two thirds (10/15) of ESBL-producing isolates would have been regarded as susceptible to
cefepime. Phenotypic ESBL detection methods were generally unreliable with these E. cloacae isolates. Based
on these results, pharmacokinetic, pharmacodynamic, and clinical reevaluation of cefepime breakpoints for E.
cloacae may be prudent.
Enterobacter cloacae is a leading cause of ventilator-associ-
ated pneumonia, bloodstream infections, and urinary tract in-
fections in hospitalized patients. A chromosomal gene in E.
cloacae characteristically encodes the AmpC beta-lactamase
(9). Mutations that increase the expression of the gene encod-
ing AmpC are responsible for the emergence of resistance of
the organism to cephalosporins such as ceftriaxone, cefo-
taxime, and ceftaxidime during therapy (4, 11). Approximately
30% of E. cloacae isolates from patients in intensive care units
in the United States are resistant to cephalosporins such as
ceftriaxone, cefotaxime, and ceftaxidime (15).
Cefepime is potentially a very useful antibiotic for the treat-
ment of serious infections with E. cloacae, even in the presence
of increased production of the AmpC beta-lactamase (23). In
vitro studies performed prior to the commercial availability of
cefepime showed that the MIC90 ranged from 0.06 to 0.5 g/ml
(12, 25, 26). In contrast, an assessment of isolates from North
American intensive care units in 2003 showed that the MIC90
was 2 g/ml, with MICs of some isolates as high as 16 g/ml
(20). In our institution in 2003, the MIC90 of cefepime for E.
cloacae bloodstream isolates was 16 g/ml. For this reason, we
sought to investigate the mechanisms of reduced cefepime sus-
ceptibility in bloodstream isolates occurring at our institution.
MATERIALS AND METHODS
Bacterial strains. Consecutive bloodstream isolates of E. cloacae from patients
at the University of Pittsburgh Medical Center (UPMC) were studied. The
isolates were collected from March 2003 through July 2004. Species identification
was done by standard biochemical tests. The strains were supplied by the hos-
pital’s clinical microbiology laboratory as part of an Institutional Review Board
approved study on mechanisms of antibiotic resistance in hospital pathogens.
Antibiotic susceptibility. The clinical microbiology laboratory at UPMC rou-
tinely assesses the MICs of cefepime and other injectable antibiotics commonly
used in the treatment of infections with gram-negative bacteria by broth microdi-
lution methods using Clinical and Laboratory Standards Institute (CLSI) criteria,
current as of 1 January 2005. Additionally, the MICs of piperacillin-tazobactam,
cefotaxime, ceftazidime, ceftazidime-clavulanic acid, cefotaxime, cefotaxime-cla-
vulanic acid, cefepime, cefepime-clavulanic acid, cefoxitin, gentamicin, ertap-
enem, imipenem, meropenem, and ciprofloxacin were determined by Etest for
the strains (AB Biodisk, Solna, Sweden). Escherichia coli ATCC 25922 and
Klebsiella pneumoniae ATCC 700603 were used as the reference strains for
antimicrobial susceptibility testing.
Analytical isoelectric focusing. Analytical isoelectric focusing was performed
on isolates with cefepime MICs of 0.5 g/ml or more, as described previously
(19). After removal of whole cells and debris by centrifugation, the supernatant
was used to determine the isoelectric point (pI). Electrophoresis was performed
using precast polyacrylamide gels, pH 3 to 10 (Bio-Rad, Hercules, CA). Enzyme
activity was detected by placing filter paper soaked in nitrocefin (500 g/ml)
(Becton Dickinson, Sparks, MD) over the focused gel. Standards from Bio-Rad
(Bio-Rad, Hercules, CA) were used, with the following isoelectric points: 4.45,
4.65, 4.75, 5.1, 6.0, 6.5, 6.8, 7.0, 7.1, 7.5, 7.8, 8.00, 8.20, and 9.6.
Plasmid profiles. The plasmid DNA of the extended-spectrum beta-lactamase
(ESBL)-producing clinical isolates was extracted with a plasmid extraction kit
(Wizard Plus Minipreps DNA purification system; Promega, Madison, WI),
according to the manufacturer’s instructions. Plasmid DNA electrophoresis was
performed with 0.8% agarose gel and visualized with ethidium bromide under
UV light.  HindIII (Promega, Madison, WI) was used as a molecular size marker.
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PFGE. Genomic DNA was isolated and digested with XbaI (New England
Biolabs, Beverly, Mass.). Pulsed-field gel electrophoresis (PFGE) was performed
with the CHEF III system (Bio-Rad, Hercules, CA) with the following run
parameters: block I, with a switch time of 3 to 65 s and a run time of 17 h, and
block II, with a switch time of 15 to 30 s and a run time of 6 h. Dendrograms were
created with BioNumerics (Bio-Rad, Hercules CA) by using the Dice coefficient,
unweighted-pair group method with arithmetic means, and a position tolerance
of 1.3%. Relatedness of the isolates was determined by the criteria of Tenover et
al. (24).
Detection of ESBL genes by PCR. Detection of genes encoding ESBLs was
attempted for all isolates with cefepime MICs of 0.5 g/ml or more. A single
colony of each test isolate was resuspended in 400 l water and boiled for 15 min.
The resulting supernatant was used as a bacterial template DNA in PCR assays.
The primers for detection of the blaTEM, blaSHV, and blaCTX-M genes are as
follows: 5-ATGAGTATTCAACATTTCCGTG-3 and 5-TTACCAATGCTTA
ATCAGTGAG-3 for blaTEM (6), 5-ATTTGTCGCTTCTTTACTCGC-3 and
5-TTTATGGCGTTACCTTTGACC-3 for blaSHV (6), and 5-CGCTTTGCG
ATGTGCAG-3 and 5-ACCGCGATATCGTTGGT-3 for blaCTX-M (2). PCRs
were performed with RedTaq DNA polymerase (Sigma, St Louis, MO), accord-
ing to the instructions of the manufacturer, in the presence of 2 l of the
template DNA preparation in a total volume of 30 l. The DNA amplification
programs consisted of an initial denaturation step (96°C, 5 min) followed by 30
cycles of denaturation (96°C, 30 s), annealing (annealing temperature designed
for each primer set, 30 s), and extension (72°C, 1 min), and a final extension of
5 min at 72°C. Ten microliters of reaction mixture containing the PCR product
was analyzed by electrophoresis in 0.8% (wt/vol) agarose (Bio-Rad, Hercules,
CA).
Sequence analysis. The amplified products were sequenced using ABI 4500
and ABI 3100 genetic analyzers according to the manufacturer’s instructions.
Sequencing reactions were performed with corresponding primers specific for
the blaTEM-1 and blaSHV-1 genes used for the previous amplification. Sequence
analysis was performed using Lasergene DNASTAR sequencing analysis soft-
ware (DNAStar, Madison, WI). Each sequence of blaTEM and blaSHV genes was
identified by comparison with known ESBL sequences available in the GenBank
and EMBL databases by multiple-sequence alignment using the BLAST program.
Phenotypic detection of beta-lactamase production. Disk diffusion testing was
performed using ceftazidime, cefotaxime, and cefepime alone (30 g each; Re-
mel, Lenexa, KS), and in combination with clavulanic acid: ceftazidime-clavu-
lanic acid, cefotaxime-clavulanic acid (30/10 g each; Becton Dickinson, Sparks,
MD), and cefepime-clavulanic acid (30/10 g; Rosco, Prolab) disks were used.
The disk tests were performed using confluent growth on Mueller-Hinton agar
(Becton Dickinson, Sparks, MD), incubated at 35°C for 24 h. The sensitivities
and specificities of phenotypic confirmatory tests for ESBL detection in Klebsiella
spp. and E. coli, but applied to E. cloacae, were determined. No interpretative
criteria for use of cefepime versus cefepime-clavulanic acid exist for any species.
Additionally, double-disk synergy tests were performed by placing disks of
ceftazidime, cefotaxime, and cefepime at distances of 20 and 30 mm (center to
center) from a disk containing amoxicillin plus clavulanic acid (20/10 g; Remel,
Lenexa, KS). A “keyhole” phenomenon was regarded as positive for ESBL
production.
MICs for cefotaxime, ceftazidime, and cefepime were determined by using
Etest strips. These MICs were compared to those obtained from the same
isolates by using Etest strips containing ceftazidime-clavulanic acid, cefotaxime-
clavulanic acid, and cefepime-clavulanic acid.
Classification of E. cloacae strains as having inducible, partially derepressed, or
derepressed AmpC production was determined by the methods of Sanders et al.
(22), in which the cefoxitin-cefotaxime antagonist test was performed (16, 22).
The E. cloacae isolates were categorized as follows: derepressed AmpC mutants
had a cefoxitin MIC of 32 g/ml, a cefotaxime MIC of 16 g/ml, and a
negative cefoxitin-cefotaxime antagonist test; partially derepressed AmpC mu-
tants had the same characteristics as derepressed AmpC mutants but with a
positive cefoxitin-cefotaxime antagonist test; and inducible AmpC-producing
strains had a cefotaxime MIC of 8 g/ml and a positive cefoxitin-cefotaxime
antagonist test (16).
RESULTS
PFGE. There was no relatedness between 41/45 isolates. All
30 isolates which were found not to be ESBL producers were
unrelated. Two of 15 ESBL producers (ES1 and ES22) were
closely related, and two additional ESBL-producing strains
(ES31 and ES43) were possibly related (data not shown).
Antibiotic susceptibility. The antibiotic susceptibilities of
the non-ESBL- and ESBL-producing E. cloacae strains are
seen in Tables 1 and 2, respectively. Forty percent (18/45) of
isolates had cefepime MICs of 0.5 g/ml or more. The distri-
bution of the cefepime MICs is shown in Fig. 1. The MIC90 for
cefepime for ESBL-producing strains was 64 g/ml, while for
non-ESBL producers it was 0.5 g/ml.
Analytical isoelectric focusing and genotypic detection of
ESBLs. Fifteen of 18 isolates with a cefepime MIC of 0.5 g/ml
or more carried ESBL genes. All of the ESBLs were of the
SHV type (Table 3). Eleven of the 15 ESBL-producing isolates
harbored blaTEM-1 in addition to blaSHV. blaCTX-M genes were
not amplified from any isolates by using our primers. The
ESBLs encoded by the E. cloacae strains included SHV-2 (one
isolate), SHV-5 (one isolate), SHV-7 (eight isolates), SHV-12
(two isolates), SHV-14 (three isolates), and SHV-30 (one iso-
late). One isolate produced both SHV-7 and SHV-30. The
isoelectric points of the isolates are presented in Table 3. The
three non-ESBL producers with cefepime MICs of 0.5 g/ml
or more produced only one beta-lactamase each, with an iso-
electric point consistent with that for AmpC.
Plasmid profile analysis. Selected ESBL-producing E. cloa-
cae strains isolated during this period were analyzed for their
plasmid content (Fig. 2; Table 3). All ESBL-producing E. clo-
acae isolates harbored plasmids, although there was diversity in
the sizes of these plasmids (Fig. 2).
Antibiotic susceptibility testing of ESBL-producing strains.
Antibiotic susceptibility testing results are shown in Table 2.
The cefepime MIC distributions of ESBL-producing isolates
were 0.5 g/ml (one isolate), 1 g/ml (one isolate), 2 g/ml
(three isolates), 4 g/ml (two isolates), 6 g/ml (one isolate), 8
g/ml (two isolates), 12 g/ml (one isolate), 16 g/ml (two
isolates), 64 g/ml (one isolate), and 256 g/ml (one isolate).
According to current CLSI breakpoints for Enterobacteriaceae,
10/15 isolates would have been regarded as cefepime suscep-
tible, 3/15 as cefepime intermediate, and 2/15 as cefepime
resistant. The majority of ESBL-producing isolates were non-
TABLE 1. Antibiotic susceptibilities (g/ml) of E. cloacae strains
without ESBL production
Antibiotic(s)
Susceptibility (g/ml) ofa:
Inducible
strains
Partially
derepressed
strains
Derepressed
mutants
Piperacillin-tazobactam 0.75–3 0.38–8 16–256
Piperacillin 0.5–64 0.5–24 32–256
Cefoxitin 0.19–6 12–128 128–256
Ceftazidime 0.125–0.5 0.094–12 12–256
Ceftazidime-clavulanic
acid
0.38–4 0.064–1.5 4
Cefotaxime 0.045–1 0.125–12 24–128
Cefotaxime-clavulanic
acid
0.125–1 0.125–1 1
Cefepime 0.032–0.094 0.064–0.5 0.125–0.75
Cefepime-clavulanic
acid
0.064–0.094 0.016–0.5 0.016–0.5
Ciprofloxacin 0.006–0.012 0.006–0.094 0.016–32
Imipenem 0.19–0.25 0.19–0.5 0.25–0.38
Gentamicin 0.25–0.5 0.094–0.75 0.25–1
a Results are shown for 4 inducible strains, 20 partially derepressed strains,
and 6 derepressed mutants.
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susceptible to numerous antibiotics: 14/15 ESBL-producing
isolates were nonsusceptible to ceftazidime, 8/15 were nonsus-
ceptible to piperacillin-tazobactam, 12/15 were nonsusceptible
to gentamicin, 8/15 were nonsusceptible to ciprofloxacin, and
2/15 were nonsusceptible to ertapenem. All 15 isolates were
susceptible to imipenem and meropenem.
Phenotypic detection of ESBL production. Applying CLSI
ESBL screening disk diffusion criteria to E. cloacae showed
that 23 isolates had a “positive” result, but 9 of these isolates
were non-ESBL producers (Table 4). Confirmatory results
were positive for 7/15 ESBL-producing strains but for no non-
ESBL-producing isolate. Applying CLSI ESBL screening MIC
criteria gave similar results (Table 5), although confirmatory
tests were positive for just 2/15 ESBL-producing strains. The
conventional double disk diffusion tests utilizing ceftazidime
and cefotaxime disks were rarely positive (Table 4).
Use of cefepime susceptibility results as a marker for ESBL
production appeared more useful (Table 6). All 13 isolates
with cefepime MICs of 2 g/ml or more were ESBL producers,
and 15/18 (83%) of isolates with cefepime MICs of 0.25
g/ml were ESBL producers. A confirmatory test with cefepime-
clavulanic acid was only 73% sensitive using disk diffusion and
53% sensitive using 3 MIC reductions (Table 6).
DISCUSSION
There are now numerous reports of E. cloacae-producing
ESBLs (1, 3, 7, 8, 10, 14, 16, 17), including several from the
FIG. 1. Distribution of cefepime MICs for E. cloacae strains with and without ESBL.
TABLE 2. MIC values of the ESBL-producing E. cloacae isolates
Isolate
MIC (g/ml) for:
Piperacillin-
tazobactam
Ceftazi-
dime
Ceftazidime-
clavulanic
acid
Cefo-
taxime
Cefotaxime-
clavulanic
acid
Cefe-
pime
Cefepime-
clavulanic
acid
Cipro-
floxacin
Erta-
penem
Imi-
penem
Mero-
penem
Genta-
micin
ES1 16 256 4 128 1 4 0.125 0.38 0.125 0.25 0.032 24
ES6 256 256 4 256 1 8 4 32 2 0.25 0.19 256
ES7 256 256 4 256 1 256 4 0.064 0.75 0.19 0.064 0.75
ES11 8 48 4 16 1 2 0.5 0.5 3 0.19 0.125 8
ES15 256 256 4 256 1 6 4 0.012 0.75 0.25 0.094 4
ES18 256 256 4 256 1 64 4 8 4 0.38 0.38 48
ES20 256 256 4 256 1 8 4 0.125 2 0.25 0.094 4
ES22 8 256 4 192 1 2 0.094 0.38 0.5 0.5 0.032 128
ES24 256 256 4 12 1 16 2 32 2 0.125 0.19 256
ES31 1.5 128 4 8 1 1 0.016 0.094 0.125 0.25 0.032 256
ES37 256 256 4 256 1 12 4 8 2 0.25 0.19 48
ES40 12 256 4 96 1 4 1.5 8 1 0.38 0.064 96
ES43 8 256 1 64 1 2 0.38 4 0.125 0.125 0.016 96
ES44 256 256 4 256 1 16 4 4 1 0.25 0.125 64
ES45 16 2 0.5 1 1 0.5 0.19 6 0.38 0.125 0.032 8
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United States (5, 13, 21). The earliest reports of ESBL-pro-
ducing E. cloacae strains from the United States were of
TEM-12 and TEM-26 producers from Boston in 1988 (21) and
SHV-3 producers from Boston in the 1990s (5). In a subse-
quent report, Levison and colleagues found SHV-7- and SHV-
12-producing E. cloacae in three different hospitals in Phila-
delphia in 2000 and 2001 (13). In Pittsburgh, we have
subsequently found SHV-2, -5, -7, -12, -14, and -30 in E. clo-
acae strains. In a 1-year period, 33% (15/45) of E. cloacae
bloodstream isolates were found to be ESBL producers. Un-
FIG. 2. Plasmids from representative ESBL-producing E. cloacae strains. Lanes 1, 9, and 17 contain  HindIII size markers. Lanes 2 to 8
contain ESBL-producing E. cloacae strains ES1, ES6, ES7, ES11, ES15, ES18, and ES22, respectively. Lanes 10 to 16 contain E. cloacae strains
ES24, ES31, ES37, ES40, ES43, ES44, and ES45, respectively.
TABLE 3. Characterization of the ESBL-producing E. cloacae isolates
Isolate Beta-lactamase characterization
Genotypic evaluation
pI PlasmidprofileSHV TEM-1
ES1 Derepressed AmpC  ESBL SHV-7 Present 5.47.69.0 P1
ES6 Derepressed AmpC  ESBL SHV-7 Present 5.47.69.0 P2
ES7 Derepressed AmpC  ESBL SHV-5 Absent 8.29.0 P3
ES11 Derepressed AmpC  ESBL SHV-14 Present 5.47.09.0 P4
ES15 Derepressed AmpC  ESBL SHV-14 Absent 7.09.0 P5
ES18 Derepressed AmpC  ESBL SHV-7 Present 5.47.69.0 P6
ES20 Derepressed AmpC  ESBL SHV-2 Absent 7.69.0 P7
ES22 Derepressed AmpC  ESBL SHV-7 Present 5.47.69.0 P1
ES24 Derepressed AmpC  ESBL SHV-7, SHV-30 Present 5.47.07.69.0 P8
ES31 Derepressed AmpC  ESBL SHV-12 Present 5.48.29.0 P9
ES37 Derepressed AmpC  ESBL SHV-7 Present 5.47.69.0 P10
ES40 Derepressed AmpC  ESBL SHV-7 Present 5.47.69.0 P11
ES43 Partially derepressed  ESBL SHV-12 Present 5.48.29.0 P9
ES44 Derepressed AmpC  ESBL SHV-7 Present 5.47.69.0 P10
ES45 Derepressed AmpC  ESBL SHV-14 Absent 7.09.0 P12
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fortunately, there are no surveillance data from the United
States in order to determine whether this percentage is high or
whether it is within the range found in similar hospitals. In a
recently published study from Korea, 43% of E. cloacae blood
culture isolates were found to be ESBL producers (16).
Wild-type E. cloacae strains obtained prior to the commer-
cial release of cefepime had cefepime MICs of 0.06 to 0.5
g/ml. It is uncertain whether any of the strains tested in these
studies produced ESBLs. In our center, the MIC90 for
cefepime for ESBL-producing strains was 64 g/ml, while for
non-ESBL producers it was 0.5 g/ml. Studies examining outer
membrane proteins, efflux pumps, and the expression levels
and hydrolytic activities of SHV-type ESBLs against cefepime
are currently under way. Thus, at the present time, we are
unable to conclusively state that the production of ESBLs is
responsible for the elevated cefepime MICs that we observed.
The clinical implications of this elevation in cefepime MIC
are under evaluation, since some patients in our series failed
cefepime therapy. Assessments of the pharmacokinetics and
pharmacodynamics of cefepime presented at CLSI Antimicro-
bial Susceptibility Testing subcommittee meetings would sug-
gest that cefepime may not be effective for treating serious
infections when dosed at 1 g every 12 h for an organism with a
MIC of 8 g/ml or higher. Clinical data from patients with
serious infections with ESBL-producing Klebsiella spp. or E.
coli would support the concept that cefepime activity may be
compromised against some ESBL-producing organisms with
MICs in the current susceptible range (18, 27). Thus, it would
appear prudent for cefepime breakpoints to be reconsidered.
Given that we have evaluated just 15 ESBL-producing iso-
lates and 30 non-ESBL-producing isolates, we cannot categor-
ically comment on ESBL detection methods for E. cloacae.
Conventional methods using cefotaxime or ceftazidime are
likely to be unreliable. However, a cefepime MIC of 2 g/ml
appears to be a consistently robust marker of ESBL produc-
tion. While tests incorporating cefepime plus clavulanic acid
may detect some ESBL producers with lower MICs, the tests
were not more than 75% sensitive in our hands.
Why would SHV-type ESBLs evolve in an E. cloacae host?
In our isolates, the SHV-type ESBLs are present in the com-
pany of a derepressed AmpC. Increased production of the
AmpC beta-lactamase confers resistance to oxyiminocephalos-
TABLE 4. Distribution of the results of different disk diffusion techniques
Test and drug Test result
Category (no. of isolates)
Sensitivity Specificity
ESBL Non-ESBL
CLSI ESBL initial screena
Ceftazidime Positive 14 9 0.93 0.70
Negative 1 21
Cefotaxime Positive 14 9 0.93 0.70
Negative 1 21
CLSI ESBL phenotypic confirmatory testb
Ceftazidime Positive 7 0 0.47 1
Negative 8 30
Cefotaxime Positive 5 0 0.33 1
Negative 10 30
Double disk diffusion test (20 mm)
Ceftazidime Positive 6 0 0.40 1
Negative 9 30
Cefotaxime Positive 7 0 0.47 1
Negative 8 30
Double disk diffusion test (30 mm)
Ceftazidime Positive 1 0 0.07 1
Negative 14 30
Cefotaxime Positive 7 0 0.47 1
Negative 8 30
a The CLSI disk inhibition break points for ESBL initial screen of E. coli and Klebsiella spp. were 22 mm for ceftazidime (30 g) and 27 mm for cefotaxime (30
g).
b A 5-mm increase in zone diameter in combination with clavulanic acid versus when tested alone.
TABLE 5. Distribution of the results of MICs obtained by Etest as
a means of ESBL detection and phenotypic confirmation
Test stage and drug Testresult
Category
(no. of isolates)
Sensitivity Specificity
ESBL Non-ESBL
Initial screeninga
Ceftazidime Positive 15 8 1 0.73
Negative 0 22
Cefotaxime Positive 15 8 1 0.73
Negative 0 22
Phenotypic
confirmationb
Ceftazidime Positive 2 0 0.13 1
Negative 13 30
Cefotaxime Positive 0 0 0 1
Negative 15 30
a The CLSI MIC breakpoints for ESBL screening for E. coli and Klebsiella spp.
were 2 g/ml or more for ceftazidime and cefotaxime.
b A 3 twofold-concentration decrease in MIC for either antimicrobial agent
tested in combination with clavulanic acid versus its MIC tested alone.
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porins and beta-lactam/beta-lactamase inhibitor combinations.
The presence of an ESBL adds a selective advantage against
cefepime. Alternatively, by production of large quantities of
AmpC, protection against cephalosporins and beta-lactamase
inhibitors may create a permissive microbiological environ-
ment within which ESBLs may evolve. It is known that ESBLs
are not catalytically efficient against penicillins and are hyper-
susceptible to beta-lactamase inhibitors. This trade-off in cat-
alytic activity would be compensated by a robust penicillinase,
TEM-1, and a cephalosporinase that is inhibitor resistant. The
net result would be expansion of resistance to cefepime.
In summary, in our center, ESBL production by E. cloacae
isolates causing serious infections is common. Thirty-three per-
cent of bloodstream isolates were ESBL producers. Occasion-
ally, patients shared genotypically similar isolates, but most
often ESBL-producing isolates appeared to arise de novo.
Given clinical concerns regarding the efficacy of cefepime
against some ESBL-producing strains, reassessment of
cefepime breakpoints by CLSI would seem prudent.
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